Bladder cancer data poise FerGene gene therapy to compete with Keytruda

Less than two weeks after its launch, Ferring’s gene therapy subsidiary has revealed data that suggest its nadofaragene firadenovec could compete with Keytruda in an early form of bladder cancer.

The adenovirus serotype 5 vector delivering IFNA2B appears to be at least as efficacious as the anti-PD-1 mAb from Merck

Read the full 493 word article

User Sign In